Table 1 Chronical list of epigenetic drugs approved for cancer by the FDA and other authorities
From: Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Name | Year of approval | Mechanisms of action | Clinical applications |
|---|---|---|---|
Azacitabine | 2004 | DNMT inhibitor | AML; CMML; MDS |
Decitabine | 2006 | DNMT inhibitor | AML; CMML; MDS |
Vorinostat | 2006 | HDAC inhibitor | Cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) |
Romidepsin | 2009 | HDAC inhibitor | CTCL and peripheral T-cell lymphoma (PTCL) |
Belinostat | 2014 | HDAC inhibitor | Relapsed or refractory PTCL |
Panobinostat | 2015 | HDAC inhibitor | Multiple myeloma |
Chidamidea | 2015 | HDAC inhibitor | Relapsed/refractory PTCL |
Enasidenib | 2017 | IDH2 inhibitor | Relapsed or refractory AML |
Ivosidenib | 2018 | IDH1 inhibitor | Relapsed or refractory AML |
Tazemetostat | 2020 | EZH2 inhibitor | Epithelioid sarcoma and relapsed or refractory follicular lymphoma |